Publications by authors named "Thittaya Audomsun"
An HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (nasal antibody spray or NAS) was developed to strengthen COVID-19 management. NAS exhibited potent broadly neutralizing activities against SARS-CoV-2 with PVNT values ranging from 0.0035 to 3.
View Article and Find Full Text PDFThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the biggest healthcare issue worldwide. This study aimed to develop a monoclonal antibody against SARS-CoV-2 from B cells of recovered COVID-19 patients, which might have beneficial therapeutic purposes for COVID-19 patients. We successfully generated human monoclonal antibodies (hmAbs) against the receptor binding domain (RBD) protein of SARS-CoV-2 using developed hybridoma technology.
View Article and Find Full Text PDFArticle Synopsis
- PD-1 is a key protein that helps to suppress the immune response against tumors, making it a critical target for cancer treatments called immune checkpoint inhibitors (ICIs).
- Researchers developed a new strategy to create effective chimeric anti-PD-1 molecules, which combine features from different sources to improve cancer therapy.
- The new chimeric antibodies created demonstrated strong ability to bind to PD-1, activating T cells similarly to existing treatments, marking them as promising candidates for future immunotherapy development.